Quantcast

Latest Paratek Pharmaceuticals Inc. Stories

2014-07-01 08:29:02

Merger to result in NASDAQ-listed biopharmaceutical company whose lead asset is a novel Phase 3-ready, oral and intravenous antibiotic drug candidate designed to address the treatment needs of patients with serious community-acquired bacterial infections. BOSTON, Mass., and POINT RICHMOND, Calif., July 1, 2014 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) and Paratek Pharmaceuticals, Inc., a privately-held biopharmaceutical company, announced today that they have entered into...

2010-09-10 06:30:00

BOSTON, Sept. 10 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced the Company's lead product, PTK 0796, a first-in-class aminomethylcycline, will be the subject of several poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Dr. Stuart Levy, co-founder and Chief Scientific Officer of Paratek will also be delivering a talk at a symposium on antibiotic resistance at the conference. ICAAC will be held in Boston,...

2009-10-15 06:00:00

BOSTON, Oct. 15 /PRNewswire/ -- Paratek Pharmaceuticals (Boston, MA) and Families of Spinal Muscular Atrophy (Elk Grove Village, IL) announced today that a jointly funded drug development program for Spinal Muscular Atrophy (SMA) has been awarded a multi-million dollar cooperative agreement from the National Institute of Neurological Disorders and Stroke (NINDS). The five-year cooperative agreement encompasses pre-clinical drug development up to the time of an Investigational New Drug...

2009-10-08 06:00:00

BOSTON, Oct. 8 /PRNewswire-FirstCall/ -- Paratek Pharmaceuticals, Inc. announced today that it has entered into an exclusive worldwide collaborative development, manufacturing and commercialization license agreement with Novartis for Paratek's lead broad-spectrum antibiotic, PTK 0796, a first-in-class aminomethylcycline (AMC) in Phase 3 clinical trials. PTK 0796 is the most advanced once-daily, oral and IV antibiotic with a spectrum that is broad enough for single-agent treatment of life...

2008-10-26 12:00:10

BOSTON, Oct. 26 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced positive Phase 2 data for the Company's lead antibiotic, PTK 0796, a first-in-class aminomethylcycline (AMC). The Phase 2 study compared safety and efficacy of oral and intravenous (IV) forms of PTK 0796 to Zyvox(R) in the treatment of patients with complicated skin and skin structure infections (cSSSIs). Paratek's trial met its primary safety and tolerability endpoint, demonstrating no differences between PTK...

2008-10-14 09:00:45

BOSTON, Oct. 14 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced the Company's lead product, amadacycline, formerly PTK 0796, a first-in-class aminomethylcycline, will be the subject of a Late Breaker poster presentation at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). ICAAC will be held in Washington, D.C. from October 25 - October 28, 2008. More information on the poster session at ICAAC: Sunday, October 26, 12:15 - 1:15 pm EST...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related